References
- Calzetta L, Ritondo BL, de Marco P. Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2020 Sep 14:1–10. Online ahead of print. DOI:10.1080/17476348.2020.1816830.
- Suissa S. Mortality in IMPACT: confounded by Asthma? Am J Respir Crit Care Med. 2020;202(5):772–773.
- Lipson DA, Dransfield MT, Han MK. Reply to Suissa: mortality in IMPACT: confounded by Asthma? Am J Respir Crit Care Med. 2020;202(5):773–777.
- Han MK, Criner GJ, Dransfield MT, et al. The effect of ICS withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study: a randomized, double-blind multicenter trial. Am J Respir Crit Care Med. 2020 Jun 25;202:1237–1243. Online ahead of print.
- Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
- Ferguson GT, Rabe K, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.
- Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.
- Martinez FJ, Han MK, Allinson JP, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(12):1540–1551.
- Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–1516.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. [cited 2020 Oct 19]. Available from: https://goldcopd.org
- Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.